Technical and Diagnostic Limitations to Partial Prostate Ablation for Prostate Cancer

Posted by Michael O. Koch, MD | Apr 2020

Michael O. Koch, MD, presented “Technical and Diagnostic Limitations to Partial Prostate Ablation for Prostate Cancer” during the 5th Annual Oklahoma Prostate & Urologic Cancers Symposium on September 13th, 2019 in Oklahoma City, Oklahoma.

How to cite: Koch, Michael O. “Technical and Diagnostic Limitations to Partial Prostate Ablation for Prostate Cancer” September 13th, 2019. Accessed Apr 2024. https://grandroundsinurology.com/technical-and-diagnostic-limitations-to-partial-prostate-ablation-for-prostate-cancer/

Technical and Diagnostic Limitations to Partial Prostate Ablation for Prostate Cancer – Summary:

Michael O. Koch, MD, the John Donohue Professor and Chair of Urology at the Indiana University School of Medicine, provides an overview of High Intensity Focused Ultrasound (HIFU) and Transurethral Ultrasound Ablation (TULSA-PRO), focal prostate ablation therapies that have recently shown promise as treatments for localized prostate cancer. Both treatments only have de novo approval from the FDA and have no specific indication for prostate cancer and there have been some disappointing international studies of the therapies. However, several studies with carefully-selected patients who are not thriving on active surveillance, have unilateral significant disease, and have limited calcifications have had remarkable results, with high rates of failure-free survival and PSA reduction. For approximately 10-15% of prostate cancer patients, prostate ablation may be a very good technique.

About The 5th Annual Prostate & Urologic Cancer Symposium:

The Prostate & Urologic Cancers Symposium is held through the University of Oklahoma and the Stephenson Cancer Center to provide new insights in the treatment of prostate and urologic cancers. This single-day program consists of lectures and case discussions highlighting a multidisciplinary approach to urologic cancer care and integration of new technology in the evaluation and treatment of patients with prostate and/or urologic cancers. Dr. Koch presented this lecture during the 5th iteration of this summit in 2019.

Please visit our collection page to view additional educational activtities from this symposium.

About The Author

Michael O. Koch, MD

Dr. Koch joined the faculty and became Chairman of the Department of Urology at Indiana University School of Medicine in 1998. He had previously been a member of the faculty at Vanderbilt University for 12 years. Dr. Koch has served in many roles related to urology nationally. Dr. Koch is a previous trustee and past-President of the American Board of Urology, past-Chairman of the Examination Committee for the American Board of Urology, past-President of the Society of Urology Chairpersons, past-President of the Society of University Chairpersons, Chair of the Residency Review Committee for Urology Training Programs, and a member of the Honorary Societies of the GU Surgeons and the Clinical Society of GU Surgeons. In 2015, he was honored by the American Urologic Association with a distinguished contribution award. In 2017, he was awarded the Health Care Hero award by the Indianapolis Business Journal for his involvement in the development of high-intensity ultrasound for the treatment of prostate cancer. He has been continuously board-certified since 1983 and is a fellow of the American College of Surgeons. He served as Chairman of the Board of the specialty physician group at Indiana University School of Medicine and currently serves in multiple capacities for his specialty, the School of Medicine, and the IU Health healthcare system. During Dr. Koch's tenure as Chairman of the Department of Urology at Indiana University, the Department has grown from 7 to 23 faculty and has risen to become one of the highest-ranked programs at IU School of Medicine.

Join the GRU Community

- Why Join? -

Share This

Chat with usLiveChat